PND48 Determinants Of Quality Of Life Of Children With Epilepsy In India  by Bansal, D. et al.
A64  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
were 32.3%, 22.0%, 13.9%, and 13.0%, respectively. These rates were similar to those 
in non-responders. Respondents with PBA symptoms (CNS-LS≥ 13) reported signifi-
cantly poorer HRQOL in all EQ-5D domains. Mean scores were worse for anxiety/
depression, pain/discomfort, and usual activities; 85% reported at least moderate 
pain or anxiety/depression; 50% reported at least moderate problems with usual 
activities. ConClusions: PBA symptoms assessed by either CNS-LS or the “invol-
untary episodes” question are prevalent among Veterans with TBI who responded 
to the survey. PBA symptoms were correlated with worse HRQOL.
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objeCtives: Electronic Patient Reported Outcomes (ePRO) such as daily diaries 
are often used in migraine clinical trials to collect information regarding migraine 
frequency, duration, severity, and symptoms. In general, alarms are an effective 
tool for prompting subjects to complete diaries on schedule. However, 70-80% of 
migraineurs suffer from phonophobia during a migraine. Thus, it is possible that 
an alarm may worsen symptoms. To address this, a decibel meter was used to 
measure the sound level of alarms on three models of the PHT LogPad handheld 
electronic device, and readings were compared to published sound aversion thresh-
olds (SAT) for migraineurs. Methods: The LogPad (LW, CV and LV) models were 
placed at a distance of one or five feet from the decibel meter. Alarm sound was 
measured on two devices in triplicate at each sound setting. Results: The SAT 
for migraineurs is reported to be approximately 76 decibels (db) (ictal) and 91 db 
(interictal). Healthy subjects have a SAT of 105 db. When the LogPad LW and decibel 
meter were placed one foot apart, the decibel meter measured 58, 67, 75, and 83 
db at the normal, medium, high and very high sound settings, respectively, and 
measured 76 db for the CV and 80 db for the LV models. When any LogPad model 
was placed five feet away from the decibel meter, all readings were below the ictal 
SAT for migraineurs. ConClusions: Even at a 1 foot distance, the alarm volume 
on the LogPad LW can be set below the ictal SAT for migraineurs and is also above 
background sound. At a distance of 5 feet, all models tested are below SAT and 
above background. Therefore, the LogPad is a suitable handheld electronic device 
to use with migraineurs that suffer from phonophobia with alarm volumes that 
can be used below SAT.
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objeCtives: To describe the frequency and nature of patient-reported out-
come (PRO) conversations between physicians and patients with Cystic 
Fibrosis. Methods: A random sample of de-identified patients with Cystic 
Fibrosis in the United States was selected from a large de-identified database 
of medical office visit transcriptions. Transcriptions were based on physician-
dictated voice recordings detailing every individual patient encounter/visit. 
De-identified medical visit transcriptions were analyzed to evaluate the burden 
associated with Cystic Fibrosis, as depicted by PRO topics observed in patient-
physician dialog in the real-world practice setting. Descriptive statistics are 
reported. Results: 333 transcriptions of medical encounters between 130 phy-
sicians (most commonly pediatricians 11%, internists 10%, pulmonologists 8%, 
general practitioners 8%, and surgeons 8%) and 183 patients over a 2-year period 
were evaluated (patient mean age: 31yrs; 27% < 18yrs, male: 55%). Non-symptom 
related PROs, including quality of life and psychosocial impacts, were discussed 
by 50 patients (27%) (10% of patients < 18yrs, 34% of patients ≥ 18yrs); the most 
commonly reported concerns were related to anxiety (n= 16(9%)), depression 
(n= 14(8%)), ability to perform daily activities (n= 7(4%)), and work/school productiv-
ity (n= 6(3%)). Symptom-related PROs were discussed by 108 patients (59%) (52% of 
patients < 18yrs, 62% of patients ≥ 18yrs); the most commonly reported symptoms 
were cough (n= 51(28%)), difficulty breathing (n= 25(14%)), and difficulty gaining/
maintaining weight (n= 15(8%)). ConClusions: PROs, as a function of disease 
burden, were routinely discussed by patients with Cystic Fibrosis. PRO discussions 
were observed more frequently among adult patients than the pediatric patients, 
and symptom-related PROs were discussed more frequently than PROs related to 
quality of life and psychosocial impacts. Modalities to alleviate this patient burden, 
including appropriate therapeutic interventions, warrant scrutiny.
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objeCtives: The objectives of this study were to assess the quality of life and 
the determinants affecting QoL in children with epilepsy using Pediatric quality 
of life questionnaire (PedsQL). Methods: A prospective observational study was 
conducted at a public hospital. In these study children less than 18 years of age, 
diagnosed with epilepsy were included. HRQoL was assessed using PedsQL, which 
comprised of 23 questions related to physical, emotional, social and school func-
tioning. After getting consent, scale was administered to both parents and subjects 
separately. Multivariate logistic regression was done to assess the potential deter-
minants of low HRQoL scores. Results: A total of 270 children with epilepsy were 
included in this study. Mean age and mean duration of antiepileptic drug treat-
ment was found to be 11.2 years and 21.6±12 months respectively. Mean total score 
according to PedsQL was found to be 89.6±6.7 (Psychological subscale score 84.7±1.2, 
physical subscale score 94.4±5.9, emotional subscale score 85.6±16, social subscale 
score 94.7±9.9 and school subscale score 73.9±12.5). Long duration of antiepileptic 
objeCtives: Huntington’s disease (HD) is a rare neurodegenerative disease lead-
ing to sustained disability for patients and poor quality of life (QoL) for patients as 
well as caregivers. This study, conducted in US as a part of an international sur-
vey, investigated a disease-specific QoL instrument, the HD QoL Battery for Carers 
(HDQoL-C). Methods: The shortened version of the HDQoL-C comprised two 
components: the satisfaction with life (3 items) and the feelings about living with 
HD (17 items). Caregivers were asked to answer socio-demographic questions and 
complete the short version of the (HDQoL-C), a previously validated questionnaire. 
Item response could be chosen among 10 possibilities depending on frequency 
or intensity. Internal validity was evaluated through the factorial structure and 
internal consistency. External validation was tested using known-group compari-
son analyses between three severity subgroups (low, moderate, high), according 
to dependence, global clinical severity and motor severity. Results: The sample 
was composed of 361 family carers from US with 76% female, 16% single and 51 of 
average age. The majority of the caregivers represented the main caregivers of the 
HD patient (73%) and 61% of them lived with the HD patient. There were 2 items 
out of 20 with potential floor effects and 3 items with ceiling effects. Cronbach’s 
alpha coefficients ranged from 0.68 to 0.90 in the whole sample, indicating high 
internal consistency Analyses of the component of HDQoL-C dealing with the feel-
ings about living with HD, demonstrated satisfactory factor analysis. Known group 
analyses showed that the HDQoL-C scores were higher for carers who cared for 
patients in the low severity group than the two other groups, meaning that these 
carers had better QoL. ConClusions: The US shortened version of the HDQoL-C 
demonstrated good internal consistency and congruent validity when compared 
to the original English version.
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objeCtives: To examine seizure severity across treatment arms among clinical 
trial subjects with refractory partial-onset seizures (POS) who participated in a 
phase III clinical trial of eslicarbazepine acetate, a novel once-daily anticonvulsant 
recently approved for the adjunctive treatment of POS in adults. Methods: The 
Seizure Severity Questionnaire (SSQ), a validated instrument developed to evaluate 
the severity and bothersomeness of specific seizure characteristics, was adminis-
tered. The SSQ total score (TS) and domain scores of frequency and helpfulness of 
warning signs before seizures (BS), severity and bothersomeness of ictal movement 
and altered consciousness during seizures (DS), cognitive, emotional, and physical 
aspects of postictal recovery after seizures (AS), and overall severity and bother 
(SB) were calculated at baseline and at the end of maintenance therapy (12-week 
duration) from the per-protocol population. ANCOVA models, adjusted for baseline 
scores, estimated least square mean (LSM) differences between arms at the end of 
therapy. Results: Among 547 subjects, average age: 38.4, 63.3% Caucasian, 50.8% 
female, 70.4% (385) had TS results at baseline and at end-of-therapy. Among subjects 
receiving 1200 mg ESL, the TS LSM was significantly lower compared to placebo (2.80 
versus 3.29, p= 0.002); the LSMs were also significantly lower for DS (3.29 versus 
3.70, p= 0.032), AS (1.95 versus 2.51, p= 0.019), and SB (3.09 versus 3.65, p< 0.001), 
but not for BS. Among subjects treated with 800 mg ESL, the LSM differences vs. 
placebo for BS, DS, AS and TS did not achieve statistical significance. The SB LSM 
was significantly lower (3.28 versus 3.65, p= 0.013). ConClusions: In this post-
hoc analysis of a phase III trial, ESL-treated subjects had statistically-significantly 
lower SSQ total scores (1200 mg), less severity and bother during seizures (1200 mg), 
less cognitive, emotional and physical impact during postictal recovery (1200 mg), 
and lower overall levels of seizure severity and bother (1200 mg and 800 mg) than 
placebo-treated subjects.
PND45
screeNiNg fOr Pba symPtOms UsiNg a siNgle qUestiON versUs a 
7 qUestiON measUre aND assessmeNt Of the assOciatiON Of Pba 
symPtOms With hrqOl bUrDeN
Fonda J.R.1, McGlinchey R.E.2, Rudolph J.L.3, Milberg W.P.2, Hunt P.R.4, Yonan C.5, Reynolds M.W.6
1VA Boston Healthcare System, Boston, MA, USA, 2Harvard Medical School, Boston, MA, USA, 
3Brigham and Women’s Hospital, Boston, MA, USA, 4Evidera, Lexington, MA, USA, 5Avanir 
Pharmaceuticals, Inc., Aliso Viejo, CA, USA, 6Evidera, Bethesda, MD, USA
bACkgRound: PBA, characterized by uncontrollable episodes of crying and/or 
laughing, often exaggerated or inappropriate to the mood state, can occur in per-
sons with neurological disorders or injury of the brain. objeCtives: Compare PBA 
survey instruments and estimate prevalence of PBA symptoms and health-related 
quality of life (HRQOL) burden in Veterans with TBI. Methods: Cross-sectional 
survey with patient-level linkage to VA clinical data. OEF/OIF Veterans screening 
positive for TBI were mailed the seven-item Center for Neurologic Study-Lability 
Scale (CNS-LS) questionnaire with an initial question asking if the Veteran had 
“involuntary episodes of crying and/or laughing that were exaggerated or even 
contrary to how they felt at the time”. The EQ-5D, a standardized HRQOL ques-
tionnaire, was included. The presence of PBA symptoms was defined in this study 
as CNS-LS score≥ 13. The sensitivity of the “involuntary episodes” question was 
assessed against the CNS-LS. Results: The 4400 Veterans mailed surveys were 
predominantly male (95%); mean(SD) age 34(8.8) years. 728 Veterans returned sur-
veys. Among respondents, 60% answered “yes” to the “involuntary episodes” ques-
tion and 70% had CNS-LS≥ 13 (PBA symptoms). The ROC curve for the ‘involuntary 
episodes’ question indicates optimal sensitivity/specificity at CNS-LS score of 12. 
Comorbidities diagnosed in the CNS-LS≥ 13 population included: PTSD (53.4%), 
major depression (34.5%), headaches/migraine (20.0%) and anxiety disorders (20.4%); 
in contrast, prevalence for the same comorbidities among Veterans with CNS-LS< 13 
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patient charts were identified (mean age: 41.2yrs; female:67%; currently treated 
with DMTs: 601(85%); discontinued DMTs in past 3 months: 35(5%); DMT-naive: 
35(10%). Of the 601 currently treated patients, current line of DMT: 1st-line-62%, 
2nd-line-28%, > = 3rd-line-10%. 1st-line patient characteristics included- mean 
age:40.0yrs; female:69%; average time-to-initiation of DMT from diagnosis:7.5mo; 
time on current 1st-line DMT:51.5months; JCV status: positive-1%/negative-7%/
don’t know-8%/not tested-84%. Top-4 reason for 1st-line DMT initiation: efficacy 
against relapses(25%), efficacy in early MS(25%), efficacy in slowing disease pro-
gression(18%), patient decision(12%). Mean EDSS-score:1.65; current disability (per-
physician-judgment): mild-81%/moderate-17%/severe-2.2%. 2nd-line DMT patient 
characteristics included- mean age:42.8yrs; female:66%; average time-to-initiation 
of DMT from diagnosis:3.7mo; time on current 2nd-line DMT:31.2months; JCV status: 
positive-14%/negative-26%/don’t know-8%/not tested-52%. Top-4 reason for choos-
ing the 2nd-line DMT: efficacy against relapses(34%), efficacy in slowing disease pro-
gression(34%), patient decision(8%), tolerability(7%); correspondingly, top-4 reasons 
for switch from 1st-line DMTs were: lack of efficacy(38%), relapse(24%), flu-like symp-
toms(17%), injection-site reactions(11%). Mean EDSS-score:2.98; current disability 
(per-physician-judgment): mild-50%/moderate-44%/severe-7%. ConClusions: In 
this cohort, RRMS patients on 2nd-line DMT appear to have higher disease burden 
compared to those on 1st-line DMT. Time-to-initiation of first DMT after diagnosis 
differed significantly between these two groups. Further research is warranted to 
scrutinize the observed treatment patterns and treatment sequencing strategies 
to alleviate patient burden.
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objeCtives: Due to a rapidly aging population, age-related diseases, such as 
Alzheimer’s disease (AD), are becoming a great concern in China. The objective of 
this study was to provide an overview of the future socio-economic issues raised by 
the increasing prevalence of AD in China. Methods: A literature review was done 
to collect information on the disease management, the demographic projections, 
and medical capabilities available in China. To answer the questions that emerged 
from the literature review, five clinical experts and two hospital administrative 
payers were interviewed. Results: It was estimated that there were 10 million 
cases of AD in China in 2010. As a typical aging disease, the burden of AD in China 
is substantial and will continue growing as the elderly population grows. Around 
33% of the Chinese population is expected to be older than 60 in 2050, representing 
438 million people. A large imbalance was found between AD management needs 
and availability of health care services for AD patients, as a result of: 1> Chinese 
culture values family care for the elderly, while the single-child policy resulting 
in 4 grand-parents and 2 parents being cared for by one child, 2> extremely poor 
awareness of AD in China both publicly and privately (assimilated as dementia), and 
3> limited medical capabilities for AD. As a result, it is predicted that working-age 
Chinese population will have to take time to provide informal care for the elderly, 
leading to an important impact on the productivity. ConClusions: Results suggest 
China is an emerging market for AD treatments. There is a large imbalance between 
AD management needs and capabilities to provide it in China.
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objeCtives: The Brazilian public health system (SUS) provides donepezil, rivastig-
mine and galantamine for all individuals with Alzheimer’s disease (AD). The Ministry 
of Health (MoH) is responsible for the acquisition of rivastigmine and donepezil, 
whereas the States are responsible for the acquisition of galantamine, reimbursed 
by MoH. The aim of this study is to characterize patients with AD and the financial 
resources employed by the MoH. Methods: Descriptive analysis of the profile of 
patients and drug expenses, based on data about the amount dispensed and values 
reimbursed by the MoH in 2012, avaliable in the database of the SUS (current values; 
exchange rate: US$ 1 = R$ 2.36). Were considered: a) MoH expenses with central 
acquisition of donepezil and rivastigmine and b) values of galantamine reimburse-
ment. Results: In 2012, 119,378 patients with AD were treated with medicines in 
the SUS. These patients had a mean age of 78.57 years and 65.87% were women. Most 
of them was treated with rivastigmine (42.98%), followed by donepezil (39.07%) and 
galantamine (17.95%). The annual costs per patient with galantamine were 17 times 
higher than donepezil (US$ 1,045.07 with galantamine, US$ 439.78 with rivastigmine 
and US$ 61.47 with donepezil). The MoH expenses in this period with these drugs 
summed up to US$ 14,176,227.12. This amount represented 0.73% of the total MoH´s 
budget of high-cost drugs in 2012. The biggest expenses occurred with rivastigmine 
(76.16%), followed by donepezil (12.09%) and galantamine (11.74%). ConClusions: 
Despite the higher cost of treatment with galantamine, the impact with rivastigmine 
was greater because it is the most common drug. The central acquisition of drugs 
results in lower treatment cost due to its scale economy and the public development 
partnerships results, a strategy aimed to strengthen the health industrial complex, 
the resource optimization and the access to medicines.
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drug treatment treatment, polytherapy, low mean seizure free interval, male gen-
der, presence of ADR and high mean duration of disease are significantly (P < 0.05) 
associated with low HRQoL scores. ConClusions: Epilepsy has a negative impact 
on their HRQoL. The determinants found by this study will help in framing different 
strategies to improve patient’s compliance and their HRQoL.
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objeCtives: Little evidence exists on the impact of herpes zoster (HZ ) on qual-
ity of life (QoL) and work absenteeism for immunocompromised patients. This 
study describes work absenteeism, and loss in quality of life due to HZ among 
immunocompromised individuals in the United States, UK, Canada, France and 
Germany. Methods: A web-based survey was conducted with adult males and 
females who: 1) had cancer or stem cell transplant (SCT) and HZ (HZ and cancer 
group); 2) cancer or SCT without HZ (cancer group); and 3) had neither cancer, SCT or 
HZ (immunocompetent group). Validated measures included the Brief Pain Inventory 
(BPI), activities of daily living (ADL), the EQ-5D-5L, and the World Health Organization 
Health and Work Performance Questionnaire (WHO HPQ) for work absenteeism. 
Multivariable logistic regressions controlling for demographic characteristics and 
comorbidities examined the impact of HZ on the EQ-5D-5L score and absenteeism 
relative to the cancer and immunocompetent groups. Results: Overall, there were 
353 respondents with HZ (HZ and cancer group), 351 with cancer only, and 353 
were immunocompetent. HZ patients had average pain scores that were at least 
2 and 3 points greater (p< 0.001) than the cancer and immunocompetent groups, 
respectively. Across all ADLs, HZ patients scored 4 and 5 points higher (p< 0.001) 
than the cancer and immunocompetent groups, respectively. HZ patients had 2 
and 20 more hours of absenteeism than the cancer and immunocompetent (p= 0.06) 
groups; and scored 0.5 and 7.3 points lower on the EQ-5D-5L than the cancer and 
immunocompetent (p= 0.01) groups. ConClusions: HZ respondents had greater 
pain, more absenteeism and lower EQ-5D-5L scores than those without HZ. Despite 
the differences between the HZ and cancer groups on ADLs and pain, these groups 
reported similar scores on the EQ-5D-5L, suggesting the EQ-5D-5L may not be sensi-
tive enough to capture the impact of HZ.
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objeCtives: Triptans have been used widely as acute treatments for migraine. 
This study aimed to determine distinct characteristics of triptan users and non-
users, identify socioeconomic-related factors associated with triptan use, define 
migraine utilization patterns and ascertain differences in cost between triptan and 
non triptan users in migraine patients. Methods: This study used the Medical 
Expenditure Panel Survey (MEPS) household component files for panels 11-14 (years 
2006-2010). Subjects who had a migraine diagnosis and were 18 years or older were 
included in the sample. Triptan users were identified from prescribed medicines 
files. Predictors associated with triptan use in migraineurs were assessed by mul-
tivariate logistic regression. Health care expenses (per person per year) including 
medical care and prescription drug expenses were measured from the payer per-
spective. The association between health expenses and triptan use was examined by 
multivariate linear regression. Results: We identified 1,644 eligible subjects in our 
study, representing 36.7 million individuals during 2006-2010 in the United States. 
Nearly 30% of the subjects received triptans to treat migraine. The triptan users 
were more likely to be women, white and have college degrees than non-users. The 
subjects receiving triptans had higher total numbers of office visits and prescription 
drug fills but lower number of emergency department visits than those not. The 
triptan expense accounted for 47% of migraine-related expenses in one year. After 
adjustment, triptan users showed 26% higher total all-cause health care expenses 
than non-users. ConClusions: Socioeconomic factors such as gender, race, educa-
tion and income levels might influence triptan use in migraineurs. Triptan treatment 
impacts on migraine-related expenses and is associated with increased total health 
care expenses in subjects with migraine.
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objeCtives: To assess treatment dynamics and disease burden among RRMS 
patients currently treated with DMTs in the US. Methods: A multi-center medi-
cal chart-review study of MS patients was conducted in 4Q2012 among neurologists 
to collect de-identified data. Neurologists were screened for duration of practice 
(> = 3yrs) and patient volume (> = 15 MS patients/month) and recruited from a large 
panel to be geographically representative of the US. Medical charts of next 10 con-
secutive MS patients were abstracted by each neurologist to collect patient diag-
nosis, treatment patterns and symptomatology/disability-status. RRMS patients 
currently treated with 1st-line & 2nd-line DMTs were evaluated. Results: 708 RRMS 
